Press Releases

Ligand to Present at the 26th Annual Roth Conference on March 11

SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.

A live webcast of the presentation will be available on the Company’s website A replay of the presentation will be archived on the site for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on maintaining and growing its large portfolio of revenue generating assets through licensing and acquisition with the goal to optimize and sustain cash-flow and profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit for more information on Captisol or for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Don Markley, 310-691-7100

Source: Ligand Pharmaceuticals